Your browser doesn't support javascript.
loading
A RARE CAUSE OF PITUITARY APOPLEXY: CABERGOLINE THERAPY.
Aydin, B; Aksu, O; Asci, H; Kayan, M; Korkmaz, H.
Affiliation
  • Aydin B; Adiyaman State Hospital, Endocrinology and Metabolic Disease, Adiyaman, Turkey.
  • Aksu O; Aydin State Hospital, Endocrinology and Metabolic Disease, Aydin, "Suleyman Demirel" University, Faculty of Medicine, Turkey.
  • Asci H; Department of Pharmacology, Turkey.
  • Kayan M; Department of Internal Medicine, Turkey.
  • Korkmaz H; Department of Radiology, Isparta, Turkey.
Acta Endocrinol (Buchar) ; 14(1): 113-116, 2018.
Article in En | MEDLINE | ID: mdl-31149244
Pituitary apoplexy (PA) is a life-threatening clinical syndrome. Dopamine receptor agonists are the drugs of choice in the treatment of prolactinomas. The use of cabergoline is reported to cause an increased risk of PA, particularly in macroprolactinomas of cystic nature. In this report, we present a patient with a cystic macroprolactinoma who developed PA on the 16th week of cabergoline treatment.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Acta Endocrinol (Buchar) Year: 2018 Document type: Article Affiliation country: Turkey Country of publication: Romania

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Acta Endocrinol (Buchar) Year: 2018 Document type: Article Affiliation country: Turkey Country of publication: Romania